

Supporting Information

Synthesis of spirotriazolines and spirooxadiazolines *via* light-induced 1,3-dipolar [3 + 2] cycloadditions

Pengfei Jia,^a Zhiqian Lin,^a Cankun Luo,^a Jiao Liang,^a Ruizhi Lai,^a Li Guo,^a Yuan Yao,^{b,*} and Yong Wu^{a,*}

^a *Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Department of Medicinal Chemistry, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, No. 17 Southern Renmin Road, Chengdu, Sichuan 610041, People's Republic of China.*

**E-mail: wyong@scu.edu.cn*

^b *Department of Geriatrics and Cardiology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, Sichuan 610041, People's Republic of China.*

**E-mail: y_yuan@scu.edu.cn*

Table of Contents

1. General information	S3
2. Experimental procedures	S3
2.1 General Procedure A: Synthesis of 2,5-diaryltetrazoles 1a-1e and 1g-1l	S3
2.2 General Procedure B: Synthesis of 2,5-diaryltetrazoles 1f and 1m-1t	S3
2.3 General Procedure C: Light-Induce 1,3-dipolar reaction between pyrazolon-derived phenyl-ketimine and 2,5-diaryltetrazoles	S4
2.4 General Procedure D: Light-Induce 1,3-dipolar reaction between isoquinoline-1,3,4(2 <i>H</i>)-triones and 2,5-diaryltetrazoles	S4
2.5 Gram-scale synthesis of spirotriazoline 3d	S5
2.6 Gram-scale synthesis of spirooxadiazoline 5d	S5
3. Detecting the reaction by ¹H NMR.....	S6
4. Irradiation lamps details	S7
5 References	S8
6. Characterization data of all compounds.....	S9
6.1 Characterization data of spirotriazolines.....	S9
6.2 Characterization data of spirooxadiazolines	S20
7. NMR spectra.....	S31

1. General information

Unless noted, all reactions were carried out in flame-dried glassware with magnetic stirring under an atmosphere of air. Chemicals and solvents were either purchased from commercial suppliers or purified by standard techniques. All the reactions were monitored by thin-layer chromatography (TLC) and were visualized using UV light. The product purification was done using silica gel column chromatography. Thin-layer chromatography (TLC) characterization was performed with precoated silica gel GF254 (0.2mm), while column chromatography characterization was performed with silica gel (100-200 mesh). NMR spectra were recorded on a Varian spectrometer (400 MHz for ^1H , 100 MHz for ^{13}C and 376 MHz for ^{19}F). Chemical shifts are reported in δ ppm referenced to an internal SiMe_4 standard for ^1H NMR and chloroform-*d* (δ 77.16) for ^{13}C NMR. Coupling constants were given in Hz. The photoreactor used in this research was the Ultraviolet high-pressure Hg lamp bought from Shanghai Bilang Instrument Co., Ltd. HRMS spectra were recorded on a Waters Q-TOF Premier. Melting points were measured with YRT-3 melting point apparatus (Shantou Keyi Instrument & Equipment Co., Ltd., Shantou, China).

Pyrazolon-derived phenyl-ketimine **2a-2d**¹, N-aryl substituted isoquinolinone, isoquinoline-1,3,4(2*H*)-triones **4a**^{2,3} were prepared according to the literature.

2. Experimental procedures


2.1 General Procedure A: Synthesis of 2,5-diaryltetrazoles 1a-1e and 1g-1l⁴

A solution of 5-phenyltetrazole (1 equiv.), aryl boronic acid (2 equiv.), and copper(I) oxide (0.05 equiv.) in DMSO (2 mL/mmol) was stirred under an O₂ atmosphere at 110 °C until full consumption of the starting material was observed. The reaction mixture was cooled, diluted with DCM, and washed successively with 1M HCl and brine. The solution was passed through a phase separator, concentrated under vacuum and purified by column chromatography.

2.2 General Procedure B: Synthesis of 2,5-diaryltetrazoles 1f and 1m-1t^{5,6}


Aldehyde (1 equiv.) was added to a solution of phenylsulfonylhydrazide (1 equiv.) in absolute ethanol (1.0 M). After stirring for 1 h at room temperature the mixture was diluted with water resulting in the precipitation of sulfonylhydrazone. The precipitate was collected by filtration, washed with aqueous ethanol and dried under vacuum and was used in the subsequent transformation without further purification. Simultaneously, a solution of NaNO₂ (1 equiv.) in H₂O (2.5 M) was slowly added to a solution of aniline (1 g, 1 equiv.) in a 50% mixture of EtOH and H₂O (0.62 M) and concentrated HCl (1.3 mL/5 mmol of aniline) at 0 °C. After 30 min, this solution was carefully added to a solution of the corresponding benzenesulfonylhydrazone (1 equiv.) in pyridine (0.16 M) at -15 °C. Once the addition is completed, the mixture was allowed to warm at rt during 1 h. After this time, HCl (10%) was added, and the resulting mixture was extracted with CHCl₃ (x3). The combined organic layers were dried over Na₂SO₄ and concentrated under vacuum. The residue was purified by flash chromatography.

2.3 General Procedure C: Light-Induce 1,3-dipolar reaction between pyrazolon-derived phenyl-ketimine and 2,5-diaryltetrazoles




A quartz vessel containing a solution of pyrazolon-derived phenyl-ketimine **2** (0.10 mmol, 1 equiv.) and the corresponding 2,5-diaryltetrazole **1** (0.15 mmol, 1.5 equiv.) in MeCN (2 mL) was irradiated with an Ultraviolet high-pressure Hg lamp for 20 h. MeCN was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, PE/EtOAc = 8/1) to give the corresponding compound **3**.

2.4 General Procedure D: Light-Induce 1,3-dipolar reaction between isoquinoline-1,3,4(2H)-triones and 2,5-diaryltetrazoles




A quartz vessel containing a solution of isoquinoline-1,3,4(2*H*)-triones **4** (0.10 mmol, 1 equiv.) and the corresponding 2,5-diaryltetrazole **1** (0.15 mmol, 1.5 equiv.) in 1,4-dioxane (2 mL) was irradiated with an Ultraviolet high-pressure Hg lamp for 18 h. 1,4-dioxane was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, PE/EtOAc = 6/1) to give the corresponding compound **5**.

2.5 Gram-scale synthesis of spirotriazoline **3d**



A round-bottom flask containing a solution of pyrazolon-derived phenyl-ketimine **2a** (1 g, 3.8 mmol, 1 equiv.) and the corresponding 2,5-diaryltetrazole **1d** (1.44g, 5.7 mmol, 1.5 equiv.) in MeCN (25 mL) was irradiated with an Ultraviolet high-pressure Hg lamp. After the reaction completed (monitored by TLC), MeCN was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, PE/EtOAc = 8/1) to give the corresponding compound **3d** as yellow solid in 88% yield (1.53 g).

2.6 Gram-scale synthesis of spirooxadiazoline **5d**



A round-bottom flask containing a solution of isoquinoline-1,3,4(2*H*)-triones **4a** (1 g, 3.98 mmol, 1 equiv.) and the corresponding 2,5-diaryltetrazole **1d** (1.51 g, 5.97 mmol, 1.5 equiv.) in 1,4-dioxane (25 mL) was irradiated with an Ultraviolet high-pressure Hg lamp. After the reaction completed (monitored by TLC), 1,4-dioxane was removed under reduced pressure, and the residue was purified by column chromatography (silica gel, PE/EtOAc = 6/1) to give the corresponding compound **5d** as yellow solid in 92% yield (1.63 g).

3. Detecting the reaction by ¹H NMR




Figure S1. Detecting the reaction by ¹H NMR

Five quartz vessels containing a solution of pyrazolon-derived phenyl-ketimine **2a**

(26.3 mg, 0.10 mmol, 1 equiv.) and the corresponding 2,5-diaryltetrazole **1a** (33.3 mg, 0.15 mmol, 1.5 equiv.) in MeCN (2 mL) was irradiated with an Ultraviolet high-pressure Hg lamp for 5 h, 10h, 15h, 20h. MeCN was removed under reduced pressure, and the residue was detected by ^1H NMR.

4. Irradiation lamps details



Figure S2. Reaction set-up. Ultraviolet high-pressure Hg lamp as UV-light irradiation (UV $\lambda = 365$ nm)


5 References

- 1 Mahajan, S.; Chauhan, P.; Kaya, U.; Deckers, K.; Rissanen, K.; Enders, D., *Chem. Commun.* **2017**, 53, 6633-6636.
- 2 Kantin, G.; Dar'in, D.; Krasavin, M., *Eur. J. Org. Chem.* **2018**, 2018, 4857-4859.
- 3 Yoshifuji, S.; Arakawa, Y., *Chem. Pharm. Bull.* **1989**, 37, 3380-3381.
- 4 Liu, C. Y.; Li, Y.; Ding, J. Y.; Dong, D. W.; Han, F. S., *Chem. – Eur. J.* **2014**, 20, 2373-2381.
- 5 Ito, S.; Tanaka, Y.; Kakehi, A.; Kondo, K.-i., *Bull. Chem. Soc. Jpn.* **1976**, 49, 1920-1923.
- 6 Ortiz-Rojano, L.; Rojas-Martin, J.; Rodriguez-Diaz, C.; Carreno, M. C.; Ribagorda, M., *Chemistry* **2019**, 25, 15050-15054.

6. Characterization data of all compounds


6.1 Characterization data of spirotriazolines

9-methyl-1,3,4,7-tetraphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3a)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1a** (33.3 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3a** as yellow solid after flash column chromatography (44.4 mg, 97% yield). M.p.: 238-239 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.68 (d, *J* = 8.1 Hz, 2H), 7.55 – 7.44 (m, 2H), 7.33 (dt, *J* = 14.1, 7.5 Hz, 3H), 7.29 – 7.23 (m, 3H), 7.18 (tt, *J* = 11.6, 6.4 Hz, 5H), 6.99 (t, *J* = 7.8 Hz, 4H), 6.88 (t, *J* = 7.3 Hz, 1H), 2.22 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.54, 158.06, 148.16, 142.82, 137.40, 137.36, 129.78, 129.55, 129.46, 129.02, 128.38, 128.05, 127.49, 126.72, 126.60, 125.80, 121.16, 119.02, 113.86, 89.18, 13.87. HRMS calcd for C₂₉H₂₃N₅NaO [M+Na]⁺: 480.1800, found for: 480.1801


1-(2-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3b)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1b** (37.8 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3b** as yellow solid after flash column chromatography (47.3 mg, 97% yield). M.p.: 225-227 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 – 7.65 (m, 2H), 7.52 – 7.47 (m, 2H), 7.39 – 7.29 (m, 3H), 7.29 – 7.22 (m, 3H), 7.17 (qd, *J* = 8.6, 7.6, 4.1 Hz, 4H), 7.08 (t, *J* = 8.2 Hz, 1H), 7.00 – 6.95 (m, 2H), 6.70 (t, *J* = 2.3 Hz, 1H), 6.45 (ddd, *J* = 8.5, 6.3, 2.3 Hz, 2H), 3.69 (s, 3H), 2.23 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.55, 160.83, 158.08, 148.09, 143.95, 137.38, 137.29, 130.35, 129.80, 129.46, 129.01, 128.37, 128.07, 127.54, 126.66, 125.80, 118.97, 107.28, 105.59, 99.54, 89.05, 55.16,

13.85. HRMS calcd for C₃₀H₂₅N₅NaO₂ [M+Na]⁺: 510.1906, found for: 510.1907.


1-(3-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3c)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1c** (37.8 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3c** as yellow solid after flash column chromatography (46.8 mg, 96% yield). M.p.: 246-247 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.69 (dd, *J* = 20.7, 7.6 Hz, 3H), 7.55 –

7.47 (m, 2H), 7.35 – 7.28 (m, 3H), 7.27 – 7.22 (m, 2H), 7.13 (dt, *J* = 9.9, 6.4 Hz, 4H), 7.03 – 6.92 (m, 4H), 6.73 (dd, *J* = 7.3, 2.1 Hz, 1H), 3.44 (s, 3H), 2.06 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 168.46, 158.11, 149.76, 149.62, 137.93, 137.57, 134.31, 129.73, 129.23, 128.87, 128.30, 128.24, 127.38, 127.01, 126.96, 124.91, 124.04, 121.50, 121.25, 118.27, 110.56, 90.23, 54.39, 14.14. HRMS calcd for C₃₀H₂₅N₅NaO₂ [M+Na]⁺: 510.1906, found for: 510.1905.

1-(4-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3d)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1d** (37.8 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3d** as yellow solid after flash column chromatography (43.9 mg, 90% yield). M.p.: 202-203 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.66 (d, *J* = 8.0 Hz, 2H), 7.53 – 7.46 (m,

2H), 7.37 – 7.29 (m, 3H), 7.26 (dd, *J* = 8.4, 6.5 Hz, 2H), 7.15 (dt, *J* = 14.6, 7.3 Hz, 4H), 7.00 (d, *J* = 8.6 Hz, 2H), 6.95 (dd, *J* = 7.5, 1.9 Hz, 2H), 6.81 – 6.74 (m, 2H), 3.71 (s, 3H), 2.22 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.43, 158.34, 155.02, 148.17, 137.62, 137.42, 137.15, 129.67, 129.40, 128.97, 128.35, 128.00, 127.15, 126.86, 126.19, 125.69, 118.96, 116.90, 114.77, 90.19, 55.50, 13.98. HRMS calcd for


C₃₀H₂₆N₅O₂ [M+H]⁺: 488.2087, found for: 488.2088.

1-(3-hydroxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3e)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1e** (35.7 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3e** as yellow solid after flash column chromatography (45.9 mg, 97% yield). M.p.: 243-244 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.65 (d, *J* = 8.0 Hz, 2H), 7.50 – 7.42 (m, 2H), 7.32 (dt, *J* = 14.8, 7.4 Hz, 3H), 7.28 – 7.20 (m, 3H), 7.16 (p, *J* = 6.9, 6.3 Hz, 4H), 7.01 – 6.93 (m, 3H), 6.74 (t, *J* = 2.3 Hz, 1H), 6.30 (ddd, *J* = 19.2, 8.1, 2.3 Hz, 2H), 2.22 (s, 3H), 1.26 (s, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.68, 158.33, 157.09, 148.30, 143.97, 137.25, 137.18, 130.54, 129.83, 129.47, 129.04, 128.38, 128.09, 127.58, 126.67, 126.53, 125.94, 119.19, 108.63, 105.18, 101.97, 89.20, 13.83. HRMS calcd for C₂₉H₂₃N₅NaO₂ [M+Na]⁺: 496.1749, found for: 496.1748.


1-(2,3-dimethylphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3f)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1f** (37.5 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3f** as yellow solid after flash column chromatography (47.1 mg, 97% yield). M.p.: 260-261 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.54 (dd, *J* = 13.0, 7.8 Hz, 4H), 7.30 (td, *J* = 9.3, 7.3, 4.3 Hz, 6H), 7.19 – 7.02 (m, 5H), 6.97 (d, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.6 Hz, 2H), 2.19 (d, *J* = 7.7 Hz, 6H), 2.12 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.42, 157.71, 149.79, 142.57, 138.15, 138.07, 137.39, 132.38, 129.73, 129.34, 128.90, 128.36, 128.09, 128.00, 127.03, 126.68, 125.79, 125.51, 125.47, 123.96, 118.88, 91.18, 20.62, 15.10, 14.64. HRMS calcd for C₃₁H₂₈N₅O [M+H]⁺: 486.2294,


found for: 486.2293.

1-(4-fluorophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3g)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1g** (36.0 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3g** as yellow solid after flash column chromatography (41.5 mg, 88% yield). M.p.: 248-249 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.69 – 7.63 (m, 2H), 7.51 – 7.45 (m, 2H), 7.38 – 7.30 (m, 3H), 7.29 – 7.22 (m, 2H), 7.22 – 7.11 (m, 4H), 7.02 – 6.89 (m, 6H), 2.23 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.35, 159.24, 158.04, 156.85, 148.58, 139.52 (d, *J* = 2.4 Hz), 137.30 (d, *J* = 4.3 Hz), 129.89, 129.49, 129.04, 128.41, 128.06, 127.46, 126.59, 126.41, 125.87, 118.94, 116.10 (d, *J* = 30.7 Hz), 116.03, 89.68, 13.90. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -122.31. HRMS calcd for C₂₉H₂₂FN₅NaO [M+Na]⁺: 498.1706, found for: 498.1705.

1-(4-chlorophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3h)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1h** (38.5 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3h** as yellow solid after flash column chromatography (44.2 mg, 90% yield). M.p.: 239-240 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.69 – 7.64 (m, 2H), 7.48 (dt, *J* = 7.0, 1.5 Hz, 2H), 7.40 – 7.30 (m, 3H), 7.29 – 7.23 (m, 2H), 7.22 – 7.12 (m, 6H), 7.00 – 6.95 (m, 2H), 6.94 – 6.90 (m, 2H), 2.22 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.20, 157.77, 148.61, 141.44, 137.23, 137.12, 129.98, 129.53, 129.48, 129.07, 128.43, 128.08, 127.65, 126.59, 126.43, 125.95, 118.95, 114.99, 89.03, 13.85. HRMS calcd for C₂₉H₂₂ClN₅NaO [M+Na]⁺: 514.1411, found for: 514.1410.

1-(4-bromophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3i)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1i** (45.2 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3i** as yellow solid after flash column chromatography (49.7 mg, 93% yield). M.p.: 269-271 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 – 7.64 (m, 2H), 7.52 – 7.46 (m, 2H), 7.39 – 7.27 (m, 6H), 7.24 (d, *J* = 1.7 Hz, 1H), 7.23 – 7.12 (m, 4H), 7.00 – 6.94 (m, 2H), 6.89 – 6.84 (m, 2H), 2.22 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.17, 157.71, 148.62, 141.82, 137.22, 137.08, 132.37, 130.00, 129.54, 129.08, 128.44, 128.09, 127.69, 126.62, 126.41, 125.96, 118.96, 115.28, 113.25, 88.91, 13.85. HRMS calcd for C₂₉H₂₂BrN₅NaO [M+Na]⁺: 558.0905, found for: 558.0906.

1-(4-iodophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3j)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1j** (52.2 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3j** as yellow solid after flash column chromatography (56.0 mg, 96% yield). M.p.: 236-237 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.62 – 7.56 (m, 2H), 7.43 – 7.37 (m, 4H), 7.29 (d, *J* = 7.7 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.21 – 7.15 (m, 3H), 7.10 (td, *J* = 9.3, 6.8 Hz, 4H), 6.92 – 6.86 (m, 2H), 6.71 – 6.64 (m, 2H), 2.14 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.16, 157.67, 148.61, 142.35, 138.22, 137.22, 137.05, 130.01, 129.55, 129.08, 128.44, 128.10, 127.72, 126.65, 126.39, 125.98, 118.96, 115.59, 88.75, 82.98, 13.85. HRMS calcd for C₂₉H₂₂IN₅NaO [M+Na]⁺: 606.0767, found for: 606.0766.

9-methyl-3,4,7-triphenyl-1-(4-(trifluoromethyl)phenyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3k)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1k** (43.5 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3k** as yellow solid after flash column chromatography (43.6 mg, 83% yield). M.p.: 251-253 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 – 7.66 (m, 2H), 7.52 – 7.44 (m, 4H), 7.41 – 7.32 (m, 3H), 7.28 (dd, *J* = 8.2, 6.6 Hz, 2H), 7.24 – 7.15 (m, 4H), 6.99 (dd, *J* = 8.0, 1.7 Hz, 4H), 2.24 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.84, 157.34, 149.10, 144.69, 137.14, 136.80, 130.18, 129.60, 129.11, 128.47, 128.17, 127.94, 126.93 (q, *J* = 3.8 Hz), 126.84, 126.18, 126.07, 124.54 (q, *J* = 270.9 Hz), 122.11 (q, *J* = 32.9 Hz), 118.96, 112.43, 88.35, 13.74. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -61.46. HRMS calcd for C₃₀H₂₂F₃N₅NaO [M+Na]⁺: 548.1674, found for: 548.1675.


1-(4-(tert-butyl)phenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3l)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1l** (41.8 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3l** as yellow solid after flash column chromatography (44.1 mg, 86% yield). M.p.: 222-223 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 – 7.66 (m, 2H), 7.51 – 7.47 (m, 2H), 7.39 – 7.32 (m, 2H), 7.32 – 7.23 (m, 4H), 7.22 – 7.10 (m, 5H), 7.00 – 6.89 (m, 4H), 2.22 (s, 3H), 1.25 (s, 9H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.70, 158.27, 147.74, 143.83, 140.32, 137.48, 137.46, 129.63, 129.41, 129.00, 128.35, 128.00, 127.36, 126.85, 126.55, 126.34, 125.73, 119.02, 113.50, 89.27, 34.12, 31.45, 13.92. HRMS calcd for C₃₃H₃₁N₅NaO [M+Na]⁺: 536.2426, found for: 536.2427.

9-methyl-1,4,7-triphenyl-3-(o-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-


one (3m)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1m** (35.4 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3m** as yellow solid after flash column chromatography (40.1 mg, 85% yield). M.p.: 206-207 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.74 – 7.68 (m, 2H), 7.43 (dd, *J* = 7.6,

1.5 Hz, 1H), 7.36 (t, *J* = 7.9 Hz, 2H), 7.26 – 7.18 (m, 4H), 7.17 – 7.11 (m, 2H), 7.10 – 7.03 (m, 3H), 6.99 (d, *J* = 8.0 Hz, 2H), 6.91 – 6.83 (m, 3H), 2.46 (s, 3H), 2.23 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.77, 157.88, 148.38, 143.22, 137.76, 137.45, 136.70, 130.93, 130.05, 129.86, 129.53, 129.33, 129.04, 127.02, 126.29, 125.86, 125.81, 125.63, 121.27, 118.99, 114.18, 88.74, 20.53, 13.96. HRMS calcd for C₃₀H₂₆N₅O [M+H]⁺: 472.2137, found for: 472.2138.

9-methyl-1,4,7-triphenyl-3-(m-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3n)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1n** (35.4 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3n** as yellow solid after flash column chromatography (42.9 mg, 91% yield). M.p.: 263-264 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.71 – 7.65 (m, 2H), 7.43 (s, 1H), 7.38

– 7.32 (m, 2H), 7.24 – 7.14 (m, 7H), 7.11 (d, *J* = 7.0 Hz, 2H), 7.02 – 6.95 (m, 4H), 6.87 (t, *J* = 7.3 Hz, 1H), 2.28 (s, 3H), 2.21 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.60, 158.08, 148.37, 142.88, 138.21, 137.43, 137.41, 130.62, 129.54, 129.40, 129.02, 128.70, 128.18, 127.42, 126.58, 125.79, 125.18, 121.12, 119.02, 113.90, 89.16, 21.39, 13.87. HRMS calcd for C₃₀H₂₆N₅O [M+H]⁺: 472.2137, found for: 472.2136.


9-methyl-1,4,7-triphenyl-3-(p-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-

one (3o)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1o** (35.4 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3o** as yellow solid after flash column chromatography (45.2 mg, 96% yield). M.p.: 273-274 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.70 – 7.65 (m, 2H), 7.40 – 7.32 (m, 4H), 7.23 – 7.17 (m, 4H), 7.17 – 7.10 (m, 2H), 7.06 (d, *J* = 7.9 Hz, 2H), 7.01 – 6.95 (m, 4H), 6.86 (t, *J* = 7.3 Hz, 1H), 2.30 (s, 3H), 2.21 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.62, 158.14, 148.28, 142.92, 139.99, 137.47, 137.43, 129.52, 129.41, 129.09, 129.01, 128.00, 127.42, 126.65, 125.78, 123.80, 121.04, 119.02, 113.86, 89.14, 21.47, 13.87. HRMS calcd for C₃₀H₂₅N₅NaO [M+Na]⁺: 494.1957, found for: 494.1958.


3-(2-methoxyphenyl)-9-methyl-1,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3p)



The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1p** (37.8 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3p** as yellow solid after flash column chromatography (47.3 mg, 97% yield). M.p.: 268-270 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.75 – 7.69 (m, 3H), 7.40 – 7.30 (m, 3H), 7.22 – 7.16 (m, 3H), 7.08 (dd, *J* = 8.3, 6.5 Hz, 2H), 7.04 – 6.97 (m, 4H), 6.90 – 6.84 (m, 3H), 6.70 (d, *J* = 8.3 Hz, 1H), 3.40 (s, 3H), 2.26 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 168.00, 158.13, 157.13, 147.60, 143.07, 137.57, 137.17, 131.86, 131.31, 129.44, 129.01, 128.91, 126.59, 125.74, 124.79, 121.08, 120.94, 119.03, 116.11, 114.22, 111.31, 88.86, 55.14, 13.84. HRMS calcd for C₃₀H₂₅N₅NaO₂ [M+Na]⁺: 510.1906, found for: 510.1907.


9-methyl-1,4,7-triphenyl-3-(4-(trifluoromethyl)phenyl)-1,2,4,7,8-

pentaazaspiro[4.4]nona-2,8-dien-6-one (3q)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1q** (43.5 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3q** as yellow solid after flash column chromatography (36.8 mg, 70% yield). M.p.: 222-224 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (d, *J* = 8.1 Hz, 2H), 7.60 (d, *J* = 8.2 Hz, 2H), 7.52 (d, *J* = 8.3 Hz, 2H), 7.36 (t, *J* = 7.9 Hz, 2H), 7.21 (qd, *J* = 8.7, 2.9 Hz, 6H), 6.99 (dd, *J* = 8.0, 5.0 Hz, 4H), 6.91 (t, *J* = 7.4 Hz, 1H), 2.23 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.22, 157.77, 146.75, 142.40, 137.27, 136.94, 131.27 (q, *J* = 32.7 Hz), 130.26, 129.70, 129.62, 129.03, 128.10, 127.90, 126.60, 125.90, 125.32 (q, *J* = 3.9 Hz), 121.55, 119.00, 113.86, 89.33, 13.85. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -62.85. HRMS calcd for C₃₀H₂₂F₃N₅NaO [M+Na]⁺: 548.1674, found for: 548.1673.

3-(4-isopropylphenyl)-9-methyl-1,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3r)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1r** (39.6 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3r** as yellow solid after flash column chromatography (48.4 mg, 97% yield). M.p.: 218-219 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.67 (d, *J* = 8.1 Hz, 2H), 7.41 (d, *J* = 8.0 Hz, 2H), 7.35 (t, *J* = 7.9 Hz, 2H), 7.19 (td, *J* = 12.4, 11.2, 3.8 Hz, 6H), 7.12 (d, *J* = 8.2 Hz, 2H), 6.99 (d, *J* = 7.8 Hz, 4H), 6.86 (t, *J* = 7.3 Hz, 1H), 2.86 (p, *J* = 6.9 Hz, 1H), 2.20 (s, 3H), 1.20 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.62, 158.14, 150.85, 148.23, 142.90, 137.50, 137.44, 129.52, 129.43, 129.01, 128.04, 127.42, 126.65, 126.50, 125.78, 124.11, 121.02, 119.03, 113.83, 89.12, 34.03, 23.77, 13.84. HRMS calcd for C₃₂H₂₉N₅NaO [M+Na]⁺: 522.2270, found for: 522.2271.

9-methyl-1,4,7-triphenyl-3-(thiophen-2-yl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3s)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1s** (34.2 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3s** as yellow solid after flash column chromatography (45.0 mg, 97% yield). M.p.: 278-279 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.68 – 7.61 (m, 2H), 7.33 (t, *J* = 7.8 Hz, 2H), 7.30 – 7.25 (m, 4H), 7.19 (dtd, *J* = 14.7, 7.8, 7.0, 3.2 Hz, 6H), 6.97 (d, *J* = 8.0 Hz, 2H), 6.90 – 6.80 (m, 2H), 6.71 (dd, *J* = 3.8, 1.1 Hz, 1H), 2.25 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.36, 157.91, 143.76, 142.72, 137.33, 136.19, 129.61, 129.56, 128.99, 128.69, 128.51, 128.38, 128.29, 127.82, 127.19, 125.80, 121.16, 119.00, 113.80, 89.48, 13.88. HRMS calcd for C₂₇H₂₁N₅NaOS [M+Na]⁺: 486.1365, found for: 486.1366.

9-methyl-1,4,7-triphenyl-3-styryl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3t)




The reaction of pyrazolon-derived phenyl-ketimine **2a** (26.3 mg, 0.1 mmol) with tetrazole **1t** (37.2 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3t** as yellow solid after flash column chromatography (46.9 mg, 97% yield). M.p.: 253-254 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.60 (d, *J* = 8.1 Hz, 2H), 7.28 (s, 1H), 7.26 – 7.16 (m, 9H), 7.16 – 7.07 (m, 5H), 6.99 (d, *J* = 16.5 Hz, 1H), 6.90 (d, *J* = 8.1 Hz, 2H), 6.79 (t, *J* = 7.3 Hz, 1H), 6.38 (d, *J* = 16.5 Hz, 1H), 2.13 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.68, 157.88, 146.80, 142.64, 137.40, 136.15, 136.04, 135.78, 129.79, 129.60, 129.02, 128.97, 128.81, 128.21, 127.29, 127.03, 125.80, 121.18, 119.00, 113.80, 112.36, 89.10, 13.89. HRMS calcd for C₃₁H₂₅N₅NaO [M+Na]⁺: 506.1957, found for: 506.1955.

4-(4-methoxyphenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3u)



The reaction of pyrazolon-derived phenyl-ketimine **2b** (29.3 mg, 0.1 mmol) with tetrazole **1a** (33.3 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3u** as yellow solid after flash column chromatography (45.4 mg, 93% yield). M.p.: 265-267 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.72 – 7.66 (m, 2H), 7.52 – 7.46 (m, 2H), 7.39 – 7.16 (m, 8H), 6.97 (td, *J* = 7.4, 7.0, 1.7 Hz, 4H), 6.90 – 6.84 (m, 1H), 6.73 – 6.66 (m, 2H), 3.68 (s, 3H), 2.25 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.71, 158.76, 158.24, 148.49, 142.91, 137.44, 129.68, 129.66, 129.52, 128.98, 128.60, 128.32, 128.07, 126.69, 125.71, 120.92, 118.97, 114.60, 113.61, 89.36, 55.35, 13.86. HRMS calcd for C₃₀H₂₅N₅NaO₂ [M+Na]⁺: 510.1906, found for: 510.1907.


4-(4-fluorophenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3v)



The reaction of pyrazolon-derived phenyl-ketimine **2c** (28.2 mg, 0.1 mmol) with tetrazole **1a** (33.3 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3v** as yellow solid after flash column chromatography (42.4 mg, 89% yield). M.p.: 233-235 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.71 – 7.63 (m, 2H), 7.52 – 7.44 (m, 2H), 7.40 – 7.16 (m, 8H), 7.04 – 6.95 (m, 4H), 6.89 (t, *J* = 8.3 Hz, 3H), 2.26 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.24, 161.41 (d, *J* = 248.7 Hz), 158.19, 148.06, 142.74, 137.26, 133.30 (d, *J* = 3.3 Hz), 129.89, 129.57, 129.05, 128.83 (d, *J* = 8.7 Hz), 128.46, 128.02, 126.41, 125.89, 121.23, 118.91, 116.48 (d, *J* = 22.9 Hz), 113.76, 89.25, 13.80. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -112.62 (tt, *J* = 8.6, 4.8 Hz). HRMS calcd for C₂₉H₂₂FN₅NaO [M+Na]⁺: 498.1706, found for: 498.1707.

4-(4-chlorophenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-


2,8-dien-6-one (3w)



The reaction of pyrazolon-derived phenyl-ketimine **2d** (29.8 mg, 0.1 mmol) with tetrazole **1a** (33.3 mg, 0.15 mmol) in MeCN (2 mL) led to compound **3w** as yellow solid after flash column chromatography (42.3 mg, 86% yield). M.p.: 217-219 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.73 – 7.67 (m, 2H), 7.51 – 7.45 (m, 2H), 7.41 – 7.26 (m, 5H), 7.25 – 7.18 (m, 3H), 7.18 – 7.13 (m, 2H), 7.02 – 6.96 (m, 2H), 6.93 – 6.86 (m, 3H), 2.22 (s, 3H). ¹³C NMR (101 MHz, Chloroform-*d*) δ 167.26, 157.97, 147.76, 142.67, 137.26, 136.06, 133.09, 129.97, 129.65, 129.58, 129.09, 128.54, 128.00, 127.70, 126.38, 125.95, 121.40, 118.93, 113.95, 89.05, 13.82. HRMS calcd for C₂₉H₂₂ClN₅NaO [M+Na]⁺: 514.1411, found for: 514.1410.


6.2 Characterization data of spirooxadiazolines

2,3',5'-triphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5a)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1a** (33.3 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5a** as yellow solid after flash column chromatography (40.1 mg, 90% yield). M.p.: 209-210 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.30 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.92 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.85 – 7.80 (m, 2H), 7.75 (td, *J* = 7.6, 1.4 Hz, 1H), 7.70 – 7.64 (m, 1H), 7.39 – 7.33 (m, 3H), 7.29 (td, *J* = 4.6, 3.8, 1.9 Hz, 2H), 7.21 – 7.12 (m, 3H), 6.98 – 6.91 (m, 1H), 6.89 – 6.82 (m, 2H), 6.79 – 6.67 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.03, 162.70, 152.65, 142.72, 136.54, 135.17, 133.76, 131.23, 130.90, 129.58, 129.38, 129.21, 128.95, 128.63, 128.21, 128.13, 126.74, 126.26, 124.64, 123.09, 117.11, 93.77. HRMS calcd for C₂₈H₁₉N₃NaO₃ [M+Na]⁺: 468.1324, found for: 468.1322.

**3'-(2-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5b)**



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1b** (37.8 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5b** as yellow solid after flash column chromatography (39.5 mg, 83% yield). M.p.: 217-218 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.26 (d, *J* = 7.4 Hz, 1H), 7.96 – 7.89 (m, 2H), 7.60 – 7.50 (m, 4H), 7.49 – 7.35 (m, 6H), 7.10 (d, *J* = 7.5 Hz, 2H), 6.98 – 6.90 (m, 2H), 6.60 (dt, *J* = 6.7, 3.7 Hz, 1H), 3.33 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.68, 163.36, 153.41, 148.90, 136.13, 134.36, 133.88, 133.14, 130.87, 130.17, 129.21, 128.80, 128.61, 128.49, 128.35, 127.31, 126.85, 126.24, 124.72, 124.36, 121.71, 121.59, 111.06, 94.05, 55.02. HRMS calcd for C₂₉H₂₁N₃NaO₄ [M+Na]⁺: 498.1430, found for: 498.1431.


**3'-(3-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5c)**



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1c** (37.8 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5c** as yellow solid after flash column chromatography (44.2 mg, 93% yield). M.p.: 213-214 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.42 – 8.33 (m, 1H), 7.98 – 7.87 (m, 3H), 7.84 – 7.77 (m, 1H), 7.75 – 7.67 (m, 1H), 7.49 – 7.34 (m, 6H), 7.08 (t, *J* = 8.1 Hz, 1H), 6.93 (d, *J* = 7.1 Hz, 2H), 6.62 (t, *J* = 2.3 Hz, 1H), 6.54 (dd, *J* = 8.3, 2.4 Hz, 1H), 6.36 (dd, *J* = 8.1, 2.2 Hz, 1H), 3.70 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.03, 162.73, 160.66, 152.29, 143.86, 136.41, 135.23, 133.86, 131.32, 130.92, 130.09, 129.60, 129.27, 128.99, 128.64, 128.21, 128.19, 126.75, 126.25, 124.61, 108.65, 108.41, 102.48, 93.47, 55.22. HRMS calcd for C₂₉H₂₂N₃O₄ [M+H]⁺: 476.1610, found for: 476.1611.


3'-(4-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-

[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5d**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1d** (37.8 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5d** as yellow solid after flash column chromatography (46.1 mg, 97% yield). M.p.: 203-205 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.32 (dd, *J* = 8.0, 1.4 Hz, 1H), 8.05 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.95 – 7.89 (m, 2H), 7.84 (td, *J* = 7.6, 1.4 Hz, 1H), 7.71 (td, *J* = 7.6, 1.3 Hz, 1H), 7.49 – 7.40 (m, 3H), 7.35 (dq, *J* = 5.2, 3.0 Hz, 3H), 6.88 – 6.83 (m, 2H), 6.80 – 6.76 (m, 2H), 6.68 (s, 2H), 3.75 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.35, 162.73, 156.99, 153.50, 136.97, 136.24, 135.02, 133.69, 131.04, 130.89, 129.30, 129.13, 128.89, 128.65, 128.15, 128.07, 126.79, 126.33, 124.75, 121.20, 114.65, 94.90, 55.62. HRMS calcd for C₂₉H₂₁N₃NaO₄ [M+Na]⁺: 498.1430, found for: 498.1431.


3'-(3-hydroxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5e**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1e** (35.7 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5e** as yellow solid after flash column chromatography (45.2 mg, 98% yield). M.p.: 233-234 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.35 (d, *J* = 7.8 Hz, 1H), 7.97 – 7.84 (m, 3H), 7.79 (t, *J* = 7.6 Hz, 1H), 7.69 (t, *J* = 7.6 Hz, 1H), 7.41 (ddt, *J* = 20.9, 13.7, 6.8 Hz, 6H), 6.96 (dt, *J* = 16.0, 7.6 Hz, 3H), 6.60 (t, *J* = 2.3 Hz, 1H), 6.40 (dd, *J* = 8.1, 2.5 Hz, 1H), 6.27 (dd, *J* = 8.0, 2.2 Hz, 1H), 5.45 (s, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.14, 162.90, 156.95, 152.39, 143.86, 136.30, 135.28, 133.75, 131.36, 130.98, 130.28, 129.65, 129.33, 129.06, 128.67, 128.20, 128.15, 126.73, 126.08, 124.49, 110.04, 108.18, 104.17, 93.47. HRMS calcd for C₂₈H₁₉N₃NaO₄ [M+Na]⁺: 484.1273, found for: 484.1272.


3'-(2,3-dimethylphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-

[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5f**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1f** (37.5 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5f** as yellow solid after flash column chromatography (19.4 mg, 41% yield). M.p.: 207-209 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.16 (ddd, *J* = 15.5, 8.0, 1.3 Hz, 2H), 7.99 – 7.93 (m, 2H), 7.85 (td, *J* = 7.6, 1.4 Hz, 1H), 7.68 (td, *J* = 7.6, 1.2 Hz, 1H), 7.50 – 7.43 (m, 3H), 7.34 (tt, *J* = 4.7, 2.5 Hz, 3H), 7.19 – 7.06 (m, 3H), 6.53 (s, 2H), 2.14 (s, 3H), 1.47 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 174.76, 167.39, 162.33, 156.92, 145.64, 137.18, 136.23, 134.74, 133.69, 132.42, 132.17, 131.07, 130.18, 129.85, 129.52, 129.36, 128.80, 128.13, 128.03, 127.13, 126.04, 123.34, 122.19, 110.62, 20.31, 12.39. HRMS calcd for C₃₀H₂₄N₃O₃ [M+H]⁺: 474.1818, found for: 474.1816.


3'-(4-fluorophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5g**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1g** (36.0 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5g** as yellow solid after flash column chromatography (36.6 mg, 79% yield). M.p.: 226-227 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.01 (d, *J* = 7.8 Hz, 1H), 7.93 – 7.82 (m, 3H), 7.74 (td, *J* = 7.7, 1.3 Hz, 1H), 7.50 – 7.35 (m, 6H), 6.98 – 6.84 (m, 4H), 6.79 (s, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.95, 162.59, 159.37 (d, *J* = 243.2 Hz), 153.25, 139.12 (d, *J* = 2.6 Hz), 136.41, 135.19, 133.61, 131.18 (d, *J* = 25.7 Hz), 129.57, 129.27, 129.03, 128.67, 128.18, 128.14, 128.04, 126.80, 126.24, 124.50, 119.70 (d, *J* = 8.0 Hz), 116.08 (d, *J* = 22.6 Hz), 94.23. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -119.11. HRMS calcd for C₂₈H₁₈FN₃NaO₃ [M+Na]⁺: 486.1230, found for: 486.1232.

3'-(4-chlorophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-


[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5h**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1h** (38.5 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5h** as yellow solid after flash column chromatography (40.8 mg, 85% yield). M.p.: 205-206 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd,

$J = 7.8, 1.4$ Hz, 1H), 7.94 (dd, $J = 7.8, 1.3$ Hz, 1H), 7.90 – 7.86 (m, 2H), 7.82 (td, $J = 7.6, 1.4$ Hz, 1H), 7.74 (td, $J = 7.6, 1.3$ Hz, 1H), 7.49 – 7.36 (m, 6H), 7.20 – 7.15 (m, 2H), 6.92 (d, $J = 7.1$ Hz, 2H), 6.88 – 6.81 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.72, 162.55, 152.64, 141.27, 135.86, 135.32, 133.68, 131.49, 131.09, 129.79, 129.35, 129.32, 129.09, 128.68, 128.17, 128.10, 127.79, 126.76, 126.20, 124.39, 117.67, 93.51. HRMS calcd for C₂₈H₁₈ClN₃NaO₃ [M+Na]⁺: 502.0934, found for: 502.0933.


3'-(4-bromophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2']-[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5i**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1i** (45.2 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5i** as yellow solid after flash column chromatography (40.9 mg, 78% yield). M.p.: 218-219 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd,


$J = 7.8, 1.4$ Hz, 1H), 7.96 – 7.85 (m, 3H), 7.82 (td, $J = 7.6, 1.4$ Hz, 1H), 7.74 (td, $J = 7.6, 1.3$ Hz, 1H), 7.50 – 7.35 (m, 6H), 7.35 – 7.28 (m, 2H), 6.94 (d, $J = 7.2$ Hz, 2H), 6.83 – 6.75 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.66, 162.54, 152.57, 141.68, 135.75, 135.33, 133.67, 132.25, 131.52, 131.10, 129.83, 129.34, 129.10, 128.69, 128.15, 128.11, 126.75, 126.20, 124.37, 117.84, 115.08, 93.38. HRMS calcd for C₂₈H₁₈BrN₃NaO₃ [M+Na]⁺: 546.0429, found for: 546.0430.

3'-(4-iodophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2']-[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5j**)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1j** (52.2 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5j** as yellow solid after flash column chromatography (42.9 mg, 75% yield). M.p.: 224-225 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 7.8, 1.4 Hz, 1H), 7.93 – 7.85 (m, 3H), 7.81 (td, *J* = 7.6, 1.5 Hz, 1H), 7.73 (td, *J* = 7.6, 1.3 Hz, 1H), 7.53 – 7.37 (m, 8H), 6.95 (d, *J* = 7.3 Hz, 2H), 6.71 – 6.65 (m, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.63, 162.54, 152.49, 142.26, 138.13, 135.67, 135.35, 133.68, 131.54, 131.11, 129.85, 129.35, 129.11, 128.69, 128.13, 126.75, 126.18, 124.36, 123.79, 118.03, 93.25, 84.94. HRMS calcd for C₂₈H₁₈IN₃NaO₃ [M+Na]⁺: 594.0291, found for: 594.0290.

2,5'-diphenyl-3'-(4-(trifluoromethyl)phenyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5k)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1k** (43.5 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5k** as yellow solid after flash column chromatography (30.8 mg, 60% yield). M.p.: 209-211 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.43 (dd, *J* = 7.7, 1.5 Hz, 1H), 7.87 (td, *J* = 7.9, 1.5 Hz, 3H), 7.78 (dtd, *J* = 21.5, 7.4, 1.5 Hz, 2H), 7.51 – 7.38 (m, 8H), 7.10 – 7.03 (m, 2H), 6.96 (d, *J* = 8.5 Hz, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.34, 162.47, 152.29, 144.71, 135.49, 135.02, 133.70, 131.76, 131.26, 130.10, 129.40, 129.20, 128.72, 128.11, 128.02, 126.78, 126.67 (q, *J* = 3.8 Hz), 126.19, 124.53 (q, *J* = 237.1 Hz), 124.16, 123.01, 114.26, 92.76. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -61.66. HRMS calcd for C₂₉H₁₈F₃N₃NaO₃ [M+Na]⁺: 536.1198, found for: 536.1199.

3'-(4-(tert-butyl)phenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5l)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1l** (41.8 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5l** as yellow solid after flash column chromatography (32.1 mg, 64% yield). M.p.: 213-214 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.35 (dd, *J* = 7.9, 1.3 Hz, 1H), 8.04 (dd, *J* = 7.8, 1.2 Hz, 1H), 7.95 – 7.89 (m, 2H), 7.84 (td, *J* = 7.6, 1.4 Hz, 1H), 7.72 (td, *J* = 7.6, 1.3 Hz, 1H), 7.48 – 7.39 (m, 3H), 7.32 (dd, *J* = 5.2, 2.0 Hz, 3H), 7.27 – 7.21 (m, 2H), 6.89 – 6.83 (m, 2H), 6.62 (s, 2H), 1.29 (s, 9H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.16, 162.74, 153.18, 147.08, 140.41, 137.08, 135.06, 133.73, 131.06, 130.84, 129.38, 129.09, 128.88, 128.62, 128.17, 128.12, 126.78, 126.29, 126.24, 124.77, 118.34, 94.44, 34.38, 31.44. HRMS calcd for C₃₂H₂₇N₃NaO₃ [M+Na]⁺: 524.1950, found for: 524.1952.

2,3'-diphenyl-5'-(*o*-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5m)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1m** (35.4 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5m** as yellow solid after flash column chromatography (31.2 mg, 68% yield). M.p.: 206-207 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.38 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.03 – 7.96 (m, 1H), 7.87 – 7.69 (m, 3H), 7.40 – 7.26 (m, 6H), 7.23 – 7.19 (m, 2H), 7.01 (t, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 7.9 Hz, 2H), 6.86 – 6.77 (m, 2H), 2.73 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.20, 162.75, 152.41, 142.81, 138.63, 136.77, 135.16, 133.80, 131.41, 131.17, 130.40, 129.60, 129.39, 129.23, 128.95, 128.34, 128.16, 128.13, 126.32, 125.82, 123.44, 122.98, 116.90, 92.67, 22.55. HRMS calcd for C₂₉H₂₁N₃NaO₃ [M+Na]⁺: 482.1481, found for: 482.1482.

2,3'-diphenyl-5'-(*m*-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5n)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1n** (35.4 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5n** as yellow solid after flash column chromatography (33.5 mg, 73% yield). M.p.: 213-214 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.37 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.98 (dd, *J* = 7.9, 1.2 Hz, 1H), 7.82 (td, *J* = 7.6, 1.4 Hz, 1H), 7.76 – 7.67 (m, 3H), 7.41 – 7.26 (m, 5H), 7.23 – 7.17 (m, 2H), 7.01 (t, *J* = 7.3 Hz, 1H), 6.95 – 6.89 (m, 2H), 6.82 (s, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.06, 162.72, 152.82, 142.77, 138.43, 136.62, 135.17, 133.78, 131.75, 131.22, 129.57, 129.37, 129.21, 128.95, 128.57, 128.20, 128.15, 127.26, 126.25, 124.49, 123.95, 123.07, 117.13, 93.70, 21.35. HRMS calcd for C₂₉H₂₁N₃NaO₃ [M+Na]⁺: 482.1481, found for: 482.1482.

2,3'-diphenyl-5'-(*p*-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5o)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1o** (35.4 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5o** as yellow solid after flash column chromatography (34.5 mg, 75% yield). M.p.: 206-208 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (d, *J* = 7.8 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.80 (dd, *J* = 10.3, 7.5 Hz, 3H), 7.71 (t, *J* = 7.6 Hz, 1H), 7.37 (dt, *J* = 7.1, 3.1 Hz, 3H), 7.22 (dt, *J* = 12.0, 5.1 Hz, 4H), 7.00 (t, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 8.0 Hz, 2H), 6.85 – 6.76 (m, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.09, 162.75, 152.87, 142.87, 141.35, 136.66, 135.16, 133.81, 131.19, 129.55, 129.36, 129.21, 128.94, 128.22, 128.15, 126.74, 126.25, 123.01, 121.82, 117.13, 93.66, 21.66. HRMS calcd for C₂₉H₂₁N₃NaO₃ [M+Na]⁺: 482.1481, found for: 482.1480.

5'-(2-methoxyphenyl)-2,3'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5p)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1p** (38.0 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5p** as yellow solid after flash column chromatography (38.0 mg, 80% yield). M.p.: 219–221 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 – 8.33 (m, 1H), 8.05 – 8.00 (m, 1H), 7.84 – 7.75 (m, 2H), 7.73 – 7.67 (m, 1H), 7.46 – 7.33 (m, 4H), 7.24 – 7.17 (m, 2H), 7.00 (dd, *J* = 9.6, 6.9 Hz, 3H), 6.96 – 6.91 (m, 2H), 6.82 (s, 2H), 3.96 (s, 3H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.22, 162.82, 158.28, 150.71, 142.93, 136.89, 135.10, 133.87, 132.16, 131.07, 129.89, 129.48, 129.28, 129.19, 128.89, 128.24, 128.16, 126.33, 123.01, 120.49, 117.31, 113.60, 111.84, 92.66, 56.23. HRMS calcd for C₂₉H₂₁N₃NaO₄ [M+Na]⁺: 498.1430, found for: 498.1429.


2,3'-diphenyl-5'-(4-(trifluoromethyl)phenyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5q**)**



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1q** (43.5 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5q** as yellow solid after flash column chromatography (28.8 mg, 56% yield). M.p.: 206–207 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.39 (dd, *J* = 7.9, 1.4 Hz, 1H), 8.04 – 7.95 (m, 3H), 7.84 (td, *J* = 7.6, 1.4 Hz, 1H), 7.75 (td, *J* = 7.6, 1.3 Hz, 1H), 7.69 (d, *J* = 8.3 Hz, 2H), 7.42 – 7.33 (m, 3H), 7.25 – 7.20 (m, 2H), 7.04 (t, *J* = 7.4 Hz, 1H), 6.96 – 6.90 (m, 2H), 6.83 (s, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.84, 162.54, 151.43, 142.24, 136.08, 135.26, 133.64, 132.32 (q, *J* = 32.7 Hz), 131.46, 129.72, 129.47, 129.27, 129.05, 128.15, 128.08, 128.02, 126.88, 126.28, 125.65 (q, *J* = 3.8 Hz), 123.78 (q, *J* = 272.3 Hz), 123.45, 117.13, 94.13. ¹⁹F NMR (376 MHz, Chloroform-*d*) δ -62.89. HRMS calcd for C₂₉H₁₈F₃N₃NaO₃ [M+Na]⁺: 536.1198, found for: 536.1199.

5'-(4-isopropylphenyl)-2,3'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-

[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5r**)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1r** (40.0 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5r** as yellow solid after flash column chromatography (33.6 mg, 69% yield). M.p.: 217-219 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (dd, *J* = 7.9, 1.4 Hz, 1H), 7.97 (d, *J* = 7.8 Hz, 1H), 7.85 – 7.78 (m,

3H), 7.71 (td, *J* = 7.6, 1.3 Hz, 1H), 7.36 (dd, *J* = 5.9, 1.7 Hz, 3H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.25 – 7.18 (m, 2H), 7.00 (t, *J* = 7.4 Hz, 1H), 6.92 (d, *J* = 8.0 Hz, 2H), 6.82 (s, 2H), 2.94 (hept, *J* = 6.9 Hz, 1H), 1.26 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.05, 162.76, 152.84, 152.24, 142.88, 136.69, 135.15, 133.82, 131.18, 129.54, 129.36, 129.20, 128.93, 128.20, 128.16, 126.89, 126.78, 126.26, 123.01, 122.17, 117.15, 93.65, 34.26, 23.81. HRMS calcd for C₃₁H₂₅N₃NaO₃ [M+Na]⁺: 510.1794, found for: 510.1795.

2,3'-diphenyl-5'-(thiophen-2-yl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-


[1,3,4]oxadiazole]-1,3(2*H*)-dione (**5s**)



The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1s** (34.2 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5s** as yellow solid after flash column chromatography (39.3 mg, 87% yield). M.p.: 220-222 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.36 (dd, *J* = 8.0, 1.4 Hz,

1H), 8.03 – 7.99 (m, 1H), 7.83 (td, *J* = 7.6, 1.4 Hz, 1H), 7.72 (td, *J* = 7.7, 1.3 Hz, 1H), 7.55 (dd, *J* = 3.7, 1.3 Hz, 1H), 7.45 (dd, *J* = 5.0, 1.3 Hz, 1H), 7.36 (dd, *J* = 5.3, 2.0 Hz, 3H), 7.21 (t, *J* = 8.0 Hz, 2H), 7.08 (dd, *J* = 5.0, 3.6 Hz, 1H), 7.02 (t, *J* = 7.4 Hz, 1H), 6.93 – 6.87 (m, 2H), 6.80 (s, 2H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 166.84, 162.64, 149.33, 142.64, 136.24, 135.19, 133.71, 131.33, 129.58, 129.39, 129.22, 129.17, 128.97, 128.27, 128.13, 127.71, 126.32, 126.16, 123.33, 117.40, 93.94. HRMS calcd for C₂₆H₁₇N₃NaO₃S [M+Na]⁺: 474.0888, found for: 474.0889.

2,3'-diphenyl-5'-styryl-1H,3'H-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2H)-dione (5t)




The reaction of isoquinoline-1,3,4(2*H*)-triones **4a** (25.1 mg, 0.1 mmol) with tetrazole **1s** (37.2 mg, 0.15 mmol) in 1,4-dioxane (2 mL) led to compound **5t** as yellow solid after flash column chromatography (42.4 mg, 90% yield). M.p.: 240-241 °C. ¹H NMR (400 MHz, Chloroform-*d*) δ 8.37 (d, *J* = 7.9 Hz, 1H), 7.95 (d, *J* = 7.8 Hz, 1H), 7.82 (t, *J* = 7.6 Hz, 1H), 7.72 (t, *J* = 7.6 Hz, 1H), 7.46 (d, *J* = 7.5 Hz, 2H), 7.40 – 7.30 (m, 7H), 7.22 – 7.16 (m, 3H), 7.00 (t, *J* = 7.3 Hz, 1H), 6.87 (d, *J* = 7.9 Hz, 3H), 6.79 (d, *J* = 16.3 Hz, 1H). ¹³C NMR (100 MHz, Chloroform-*d*) δ 167.02, 162.67, 152.81, 142.29, 136.84, 136.43, 135.32, 135.26, 133.78, 131.32, 129.64, 129.43, 129.36, 129.27, 129.02, 128.93, 128.21, 128.15, 127.30, 126.22, 123.07, 116.79, 110.63, 93.37. HRMS calcd for C₃₀H₂₁N₃NaO₃ [M+Na]⁺: 494.1481, found for: 494.1480.


7. NMR spectra

9-methyl-1,3,4,7-tetraphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3a)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




1-(2-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3b)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(3-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3c)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(4-methoxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3d)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




1-(3-hydroxyphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3e)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(2,3-dimethylphenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3f)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(4-fluorophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3g)


^1H NMR (CDCl_3 , 400 MHz)



^{13}C NMR (CDCl_3 , 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




1-(4-chlorophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3h)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(4-bromophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3i)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




1-(4-iodophenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3j)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




9-methyl-3,4,7-triphenyl-1-(4-(trifluoromethyl)phenyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3k)


^1H NMR (CDCl_3 , 400 MHz)



^{13}C NMR (CDCl_3 , 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




1-(4-(tert-butyl)phenyl)-9-methyl-3,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3I)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-(o-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3m)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-(m-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3n)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-(p-tolyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3o)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




3-(2-methoxyphenyl)-9-methyl-1,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3p)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-(4-(trifluoromethyl)phenyl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3q)


^1H NMR (CDCl_3 , 400 MHz)



^{13}C NMR (CDCl_3 , 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




3-(4-isopropylphenyl)-9-methyl-1,4,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3r)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-(thiophen-2-yl)-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3s)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




9-methyl-1,4,7-triphenyl-3-styryl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one

(3t)

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




4-(4-methoxyphenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3u)

^1H NMR (CDCl_3 , 400 MHz)




^{13}C NMR (CDCl_3 , 100 MHz)




4-(4-fluorophenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3v)


^1H NMR (CDCl_3 , 400 MHz)



^{13}C NMR (CDCl_3 , 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




4-(4-chlorophenyl)-9-methyl-1,3,7-triphenyl-1,2,4,7,8-pentaazaspiro[4.4]nona-2,8-dien-6-one (3w)

$^1\text{H NMR}$ (CDCl_3 , 400 MHz)




$^{13}\text{C NMR}$ (CDCl_3 , 100 MHz)




2,3',5'-triphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione
(5a)

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(2-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5b)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(3-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5c)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(4-methoxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5d)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(3-hydroxyphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5e)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(2,3-dimethylphenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5f)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(4-fluorophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5g)**


¹H NMR (CDCl₃, 400 MHz)



¹³C NMR (CDCl₃, 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




**3'-(4-chlorophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5h)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(4-bromophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5i)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**3'-(4-iodophenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5j)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




2,5'-diphenyl-3'-(4-(trifluoromethyl)phenyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5k)


¹H NMR (CDCl₃, 400 MHz)



¹³C NMR (CDCl₃, 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




**3'-(4-(tert-butyl)phenyl)-2,5'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (51)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




2,3'-diphenyl-5'-(*o*-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5m)

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**2,3'-diphenyl-5'-(m-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-
1,3(2*H*)-dione (5n)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




2,3'-diphenyl-5'-(p-tolyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5o)

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**5'-(2-methoxyphenyl)-2,3'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5p)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




2,3'-diphenyl-5'-(4-(trifluoromethyl)phenyl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5q)


¹H NMR (CDCl₃, 400 MHz)



¹³C NMR (CDCl₃, 100 MHz)




^{19}F NMR (CDCl_3 , 376 MHz)




5'-(4-isopropylphenyl)-2,3'-diphenyl-1*H*,3'*H*-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2*H*)-dione (5r)

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)




**2,3'-diphenyl-5'-(thiophen-2-yl)-1*H*,3'*H*-spiro[isoquinoline-4,2'-
[1,3,4]oxadiazole]-1,3(2*H*)-dione (5s)**

¹H NMR (CDCl₃, 400 MHz)




¹³C NMR (CDCl₃, 100 MHz)



2,3'-diphenyl-5'-styryl-1H,3'H-spiro[isoquinoline-4,2'-[1,3,4]oxadiazole]-1,3(2H)-dione (5t)

^1H NMR (CDCl_3 , 400 MHz)



^{13}C NMR (CDCl_3 , 100 MHz)

